Luvometinib in Combination With Serplulimab for NF2-Related Tumors
A Multicenter, Open-Label Study of Luvometinib in Combination With Serplulimab for the Treatment of NF2-Related Tumors
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
NF2-related schwannomatosis (NF2-SWN) is a rare autosomal dominant disorder characterized by multiple central nervous system tumors, most commonly vestibular schwannomas and meningiomas. Although current treatments such as surgery and radiotherapy can provide disease control, they are not curative and are associated with cumulative neurological morbidity and potential risk of secondary malignancies. There remains a significant unmet need for effective systemic therapies.
This investigator-initiated study is conducted as a substudy within the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The trial evaluates luvometinib in combination with serplulimab in patients with progressive NF2-SWN.
Luvometinib (FCN-159) is a selective MEK1/2 inhibitor with antitumor activity in NF1-associated tumors. Serplulimab (HLX10) is an anti-PD-1 monoclonal antibody approved for multiple solid tumors. Preclinical evidence suggests that MEK inhibition may enhance tumor immunogenicity and synergize with immune checkpoint blockade.
The study aims to assess the safety, tolerability, and preliminary efficacy of this combination in NF2-SWN.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100853
- Chinese PLA General Hospital
-
Contact:
- Jun Zhang, MD, PhD
- Telefoonnummer: 86+ 10-68182255
- E-mail: junzhang301@163.com
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Pinan Liu, MD, PhD
- Telefoonnummer: 86+ 10-59976611
- E-mail: pinanliu@ccmu.edu.cn
-
Beijing, Beijing Municipality, China, 100053
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Hao Wu, MD, PhD
- Telefoonnummer: +86 10-83922345
- E-mail: wuhaospine@xwh.ccmu.edu.cn
-
-
Jilin
-
Changchun, Jilin, China
- The First Hospital of Jilin University
-
Contact:
- Yunqian Li, MD, PhD
- Telefoonnummer: 86+ 431-88782222
- E-mail: yunqian@jlu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200080
- Shanghai General Hospital
-
Contact:
- Meiqing Lou, MD, PhD
- Telefoonnummer: +86 21-63846590
- E-mail: loumq68128@hotmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Participants must meet the diagnostic criteria for NF2-SWN.
- Presence of at least one measurable target tumor, either vestibular schwannoma or meningioma, with MRI-documented volumetric progression within the past 36 months or clinical symptom progression related to the target tumor.
- The target tumor is considered unsuitable for surgery because of high risk.
- Age >=18 years at the time of screening.
- KPS >=70 or ECOG performance status 0 or 1.
- Adequate organ function based on laboratory tests obtained within 14 days before screening.
- Participant must be able to understand the study and voluntarily sign informed consent.
Exclusion Criteria:
- Pregnant, planning to become pregnant, or currently breastfeeding.
- Participation in another interventional clinical trial within the past 4 weeks, or radiation therapy to target lesion(s) within the past 3 years.
- Severe adverse reactions or intolerable toxicity from prior immune checkpoint inhibitors or MEK inhibitors.
- Concomitant active malignancies, uncontrolled infections, or active autoimmune diseases.
- Severe cardiac, hepatic, renal, gastrointestinal, or ophthalmic diseases.
- Any other factor that may compromise participant safety or study integrity.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Luvometinib + Serplulimab
Subjects will receive luvometinib 8 mg by mouth once daily in combination with serplulimab 4.5 mg/kg intravenously every 3 weeks for up to 12 cycles (28 days per cycle).
|
Oral once daily per predetermined dosage per protocol.
Andere namen:
Intravenous infusion per predetermined dosage per protocol.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR) or Hearing Response Rate (HRR)
Tijdsspanne: 12 months
|
Vestibular schwannoma: HRR is defined as WRS improvement exceeding the 95% critical difference from baseline; if baseline WRS is <20%, HRR is defined as a PTA decrease of at least 10 dB. Meningioma: ORR is defined as at least a 20% reduction in target tumor volume from baseline. |
12 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Adverse Events
Tijdsspanne: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who experience at least one adverse event.
Adverse events will be coded and graded according to NCI CTCAE v5.0.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Maximum Severity Grade of Adverse Events
Tijdsspanne: From first dose through 30 days after last dose (up to 12 months)
|
Maximum NCI CTCAE v5.0 grade of adverse events experienced by each participant during the reporting period.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Serious Adverse Events
Tijdsspanne: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who experience at least one serious adverse event.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Dose Modifications
Tijdsspanne: From first dose through 30 days after last dose (up to 12 months)
|
Percentage of participants who require at least one dose modification due to an adverse event.
|
From first dose through 30 days after last dose (up to 12 months)
|
|
Incidence of Treatment Interruptions
Tijdsspanne: From first dose through 30 days after last dose.
|
Percentage of participants who require at least one treatment interruption due to an adverse event.
|
From first dose through 30 days after last dose.
|
|
Incidence of Treatment Discontinuations
Tijdsspanne: From first dose through 30 days after last dose.
|
Percentage of participants who discontinue study treatment due to an adverse event.
|
From first dose through 30 days after last dose.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het zenuwstelsel
- Neoplasmata per site
- Neoplasmata
- Genetische ziekten, aangeboren
- Neoplasmata per histologisch type
- Neurodegeneratieve ziekten
- KNO-ziekten
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neoplasmata van het zenuwstelsel
- Heredodegeneratieve aandoeningen, zenuwstelsel
- Zenuwschede neoplasmata
- Neoplastische syndromen, erfelijk
- Neurocutane syndromen
- Neoplasmata van het perifere zenuwstelsel
- Neuro-endocriene tumoren
- Oor Ziekten
- Otorinolaryngologische neoplasmata
- Neoplasmata, vaatweefsel
- Meningeale neoplasmata
- Neoplasmata van het centrale zenuwstelsel
- Ziekten van de hersenzenuw
- Neuroma
- Craniale zenuwneoplasmata
- Vestibulocochleaire zenuwaandoeningen
- Retrocochleaire ziekten
- Neurofibroom
- Neurilemmoom
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Neurofibromatose
- Meningeoom
- Neuroma, akoestisch
- Neurofibromatose 2
Andere studie-ID-nummers
Andere studie-ID-nummers
- HX-A-2026035
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .